B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia

Clinical and Experimental Immunology

Volumn 170, Issue 2, 2012, Pages 231-237

  Lake Bakaar, G ^a   Jacobson, I ^a   Talal, A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

B cell activating factor; Hepatitis C virus; Interferon; Mixed cryoglobulinaemia; Rituximab

Indexed keywords

B CELL ACTIVATING FACTOR; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITUXIMAB; VIRUS RNA;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNE DEFICIENCY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CRYOGLOBULINEMIA; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL;

EID: 84867194082     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04653.x     Document Type: Article

References (40)

1. Krivosikova M, Dallos T, Maslinski W, Buc M. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases. Bratisl Lek Listy 2009; 110:137-145.
2. Lesley R, Xu Y, Kalled SL etal. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441-453.
3. Thien M, Phan TG, Gardam S etal. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20:785-798.
4. Sutherland AP, Ng LG, Fletcher CA etal. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005; 174:5537-5544.
5. Sene D, Limal N, Ghillani-Dalbin P etal. Virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxf) 2007; 46:65-69.
6. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia MT, Zignego AL. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 2003; 21:S78-84.
7. De Vita S, De Re V, Gasparotto D etal. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43:94-102.
8. Ramos-Casals M, Garcia-Carrasco M, Cervera R etal. Th1/Th2 cytokine imbalance in patients with Sjogren syndrome secondary to hepatitis C virus infection. Semin Arthritis Rheum 2002; 32:56-63.
9. De Vita S, Quartuccio L, Isola M etal. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843-853.
10. Gragnani L, Piluso A, Giannini C etal. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011; 63:1446-1451.
11. Giannini C, Gragnani L, Piluso A etal. Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood 2008; 112:4353-4354.
12. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9:491-502.
13. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-1495.
14. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin Liver Dis 2000; 20:143-157.
15. Toubi E, Gordon S, Kessel A etal. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27:134-139.
16. Atta AM, Oliveira IS, Sousa GM, Parana R, Atta ML. Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. Microb Pathog 2010; 48:53-56.
17. Neumann AU, Lam NP, Dahari H etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
18. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93:4398-4402.
19. Zaaijer HL, Bouter S, Boot HJ. Substitution rate of the hepatitis B virus surface gene. J Viral Hepat 2008; 15:239-245.
20. Luciani F, Alizon S. The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput Biol 2009; 5:e1000565.
21. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88:3392-3396.
22. Novak AJ, Grote DM, Ziesmer SC etal. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24:983-987.
23. Novak AJ, Slager SL, Fredericksen ZS etal. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009; 69:4217-4224.
24. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3:424-429.
25. Ittah M, Miceli-Richard C, Eric Gottenberg J etal. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006; 8:R51.
26. Ittah M, Miceli-Richard C, Gottenberg JE etal. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008; 38:1058-1064.
27. Ittah M, Miceli-Richard C, Lebon P, Pallier C, Lepajolec C, Mariette X. Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. J Innate Immun 2010; 3:200-207.
28. Wan S, Zhou Z, Duan B, Morel L. Direct B cell stimulation by dendritic cells in a mouse model of lupus. Arthritis Rheum 2008; 58:1741-1750.
29. Krumbholz M, Theil D, Derfuss T etal. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201:195-200.
30. Gandhi KS, McKay FC, Schibeci SD etal. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. J Interferon Cytokine Res 2008; 28:529-539.
31. Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler 2010; 17:567-577.
32. De Blasi T, Aguilar Marucco D, Cariti G, Maiello A, De Rosa FG, Di Perri G. Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. Infection 2008; 36:285-287.
33. Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005; 24:507-515.
34. Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L. Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 2004; 16:701-703.
35. Dammacco F, Tucci FA, Lauletta G etal. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116:343-353.
36. Tarantino G, Marco VD, Petta S etal. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. J Viral Hepat 2009; 16:397-405.
37. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
38. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66:700-703.
39. Vallerskog T, Heimburger M, Gunnarsson I etal. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R167.
40. Zarkhin V, Li L, Sarwal MM. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 2009; 88:1229-1230.